Literature DB >> 8867862

Safety and efficacy of in vivo gene transfer into the porcine heart with replication-deficient, recombinant adenovirus vectors.

J Mühlhauser1, M Jones, I Yamada, C Cirielli, P Lemarchand, T R Gloe, B Bewig, S Signoretti, R G Crystal, M C Capogrossi.   

Abstract

Gene transfer with replication-deficient recombinant adenovirus (Ad) vectors may provide a novel approach to the treatment of some cardiac disorders. The relative efficiency of intramyocardial vs intracoronary Ad vector injection in transducing myocardial cells remains to be determined. Further, Ad vectors are associated with localized inflammation, and this could be associated with clinically significant side-effects. Female minipigs underwent open chest surgery and the Ad vector AdCMV.NLS beta-gal was injected into the circumflex coronary artery (IC; 2 x 10(10) p.f.u.; n = 5) or the posterobasal wall of the left ventricle (i.m.; 5 x 10(9) p.f.u., n = 4; 2 x 10(10) p.f.u., n = 18). The minipigs were killed after 2-31 days and the hearts examined for evidence of beta-galactosidase activity. Minipigs underwent epicardial echocardiography immediately before, within 15 min following the i.m. injection of AdCMV.NLS beta-gal and again at the time of death. Blood samples for white blood cell count, alkaline phosphatase, total bilirubin, blood urea nitrogen, creatinine and electrolytes were obtained before i.m. and i.c. injection of the Ad vector and before death. Intramuscular injection of the Ad vector was more efficient than i.c. infusion in infecting cells in a localized area of the heart. Myocardial beta-gal activity peaked at 3-6 days after i.m. injection and returned to its control value within 1 month. Although inflammatory cells were present at the injection site, echocardiograms did not show any evidence of either segmental or global left ventricular dysfunction. No minipigs died and all blood tests remained within normal limits following either i.m. or i.c. exposure to the Ad vector. In summary, direct i.m. administration of replication-deficient, recombinant Ad vectors provides a safe and effective approach for short-term gene transfer into the heart of large mammals.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8867862

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  21 in total

Review 1.  Percutaneous approaches for efficient cardiac gene delivery.

Authors:  Kiyotake Ishikawa; Jaume Aguero; Charbel Naim; Kenneth Fish; Roger J Hajjar
Journal:  J Cardiovasc Transl Res       Date:  2013-06-08       Impact factor: 4.132

Review 2.  Cardiac gene therapy: optimization of gene delivery techniques in vivo.

Authors:  Michael G Katz; JaBaris D Swain; Jennifer D White; David Low; Hansell Stedman; Charles R Bridges
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

3.  Ultrarapid, highly efficient viral gene transfer to the heart.

Authors:  J K Donahue; K Kikkawa; D C Johns; E Marban; J H Lawrence
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

4.  Prolonged cardiac allograft survival using iodine 131 after human sodium iodide symporter gene transfer in a rat model.

Authors:  D Ricci; A A Mennander; N Miyagi; V P Rao; H D Tazelaar; K Classic; G W Byrne; S J Russell; C G A McGregor
Journal:  Transplant Proc       Date:  2010-06       Impact factor: 1.066

Review 5.  Current strategies for myocardial gene delivery.

Authors:  Michael G Katz; JaBaris D Swain; Catherine E Tomasulo; Marina Sumaroka; Anthony Fargnoli; Charles R Bridges
Journal:  J Mol Cell Cardiol       Date:  2010-09-15       Impact factor: 5.000

Review 6.  Angiogenesis gene therapy to rescue ischaemic tissues: achievements and future directions.

Authors:  C Emanueli; P Madeddu
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

7.  Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs.

Authors:  B G Harvey; N R Hackett; T El-Sawy; T K Rosengart; E A Hirschowitz; M D Lieberman; M L Lesser; R G Crystal
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

8.  Gene therapy approaches to ventricular tachyarrhythmias.

Authors:  J Kevin Donahue; Tetsuo Sasano; Kamilla Kelemen
Journal:  J Electrocardiol       Date:  2007 Nov-Dec       Impact factor: 1.438

9.  A replication-incompetent adenovirus vector with the preterminal protein gene deleted efficiently transduces mouse ears.

Authors:  J W Moorhead; G H Clayton; R L Smith; J Schaack
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

Review 10.  Mechanistic, technical, and clinical perspectives in therapeutic stimulation of coronary collateral development by angiogenic growth factors.

Authors:  Gabor M Rubanyi
Journal:  Mol Ther       Date:  2013-02-12       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.